—The misconception that our report is contradictory deserves a reply, and we welcome the opportunity to further discuss and clarify the intent, design, results, and recommendations of the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity (CRYO-ROP).This study was designed to test the results of cryotherapy for a defined threshold severity of ROP occurring posterior to zone 3 of the retina. It would have been presumptuous to test for the optimal stage (or other variables) at which to apply a treatment for which efficacy had not previously been adequately studied.The subgroup of zone 1 cases, when separately analyzed, contains an insufficient sample size to demonstrate a significant benefit in that particular subgroup, even if it exists. However, as our report stated, cryotherapy clearly benefits threshold stage 3+ ROP in zone 2, and the data are consistent with the finding that it also benefits some cases of
Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Quinn GE, Schaffer DB. Cryotherapy for Retinopathy of Prematurity: None, One, or Both Eyes-Reply. Arch Ophthalmol. 1990;108(10):1375–1376. doi:10.1001/archopht.1990.01070120021004
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: